Fig. 4From: Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapyDuration of therapy for first IO regimen in the monotherapy and combination therapy subgroups. aPatients whose end of follow-up date (eg, date of last contact with TO) was on their index date were excluded from the analytical subset (no observed follow-up time), as were patients with unknown line of therapy start or end dates. Kaplan-Meier curves were truncated at 6 months from the index date, the maximum observation period. Shaded areas around the curves represent 95% CIs. CI confidence interval; IO immuno-oncology; NE not estimable; Pts patients; TO Tennessee oncologyBack to article page